Healthcare
Mirum Pharmaceuticals, Inc.(MIRM)
Live Price
Offline$107.13
+4.99% today
1Y Change
+114.98%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $4.85B
- Revenue Growth
- +54.7%
- EPS Growth
- +74.6%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Mirum Pharmaceuticals, Inc. (MIRM) is a Healthcare stock with a market cap of $4.85B and listed on NASDAQ. The stock last traded around $107.13 and up 115.0% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +54.7%, EPS growth of +74.6%, a dividend yield of 0.0%. What stands out right now is revenue +54.7%, EPS +74.6%, free cash flow +488.0% with operating margin -4.2% and ROIC -3.5%. Valuation already assumes a fairly strong business story at price/sales 9.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MIRM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+54.7% vs +7.6% peer median
Operating Margin
Below sector median
-4.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +54.7% and EPS at +74.6%, with operating margin around -4.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -6.5% | -0.8% | -16.0% |
2026 Feb 25, 2026 | -650.0% | -15.1% | -14.3% | -17.0% |
2025 Nov 4, 2025 | +150.0% | -1.2% | +0.5% | +0.0% |
Benchmark Edge
MIRM vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MIRM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MIRM Max Drawdown
-20.55%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MIRM and SPY.
Company Overview
Mirum Pharmaceuticals, Inc.
NASDAQ Global Market
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
- Leadership
- Christopher Peetz
- IPO Date
- Jul 18, 2019
- Employees
- 334
- Street Address
- 950 Tower Lane
- Mailing
- Foster City, CA, 94404
- Region
- Foster City, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 667 4085
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 348.9
- Price/Sales
- 9.3
- Price/Book
- 15.4
Growth
- Revenue
- +54.7%
- EPS
- +74.6%
- Free Cash Flow
- +488.0%
Profitability
- Gross Margin
- 80.8%
- Operating Margin
- -4.2%
- Net Margin
- -4.5%
- ROE
- -8.5%
- ROIC
- -3.5%
Balance Sheet
- Debt/Equity
- 1.02
- Current Ratio
- 2.67
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.